Galera Therapeutics Announces Dosing of First Patient in a Randomized ...

The randomized, double-blind, placebo-controlled Phase 2 trial is designed to assess the safety and efficacy of GC4419 in improving 28-day mortality, compared to placebo. The trial will enroll up ... Read More

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 ...

Trial Supported in Part by NIH SBIR GrantMALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing ... Read More

Seneca Therapeutics Announces the Dosing of the First Patient in the ...

The Phase I/II trial will assess the safety and preliminary efficacy of Seneca Valley Virus (SVV-001) in combination with the checkpoint inhibitors nivolumab and ipilimumab in the treatment of ... Read More

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long ...

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial -New Long-COVID Research Program Complements Fibromyalgia Phase 2b Clinical Research Program- ... Read More

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double ...

“The results of Napo’s randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients are expected to be available in the second half of 2026. Read More

Spyre Therapeutics Announces Positive Interim Phase 1 Results ... - KTLA

The SPY002 and SPY072 Phase 1 trials are first-in-human, randomized, double-blind, placebo-controlled trials designed to evaluate safety, PK, and PD in healthy volunteers. Read More

BioCardia Announces First Patient in Phase 3 Randomized Controlled ...

A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial, American College of Cardiology Scientific Sessions ... Read More

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a ...

The initiation of this Phase 1 trial represents an important step in the clinical evaluation of ATR as a target for cancer therapy." About Aprea Therapeutics, Inc. Read More

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial ...

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Company fully funded into 2025 with full readouts of ... Read More

Galera Therapeutics Announces Dosing of First Patient in a Randomized ...

The randomized, double-blind, placebo-controlled Phase 2 trial is designed to assess the safety and efficacy of GC4419 in improving 28-day mortality, compared to placebo. The trial will enroll up ... Read More

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 ...

“We are extremely excited to announce the dosing of the first patient in the PE trial,” said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. Read More